Literature DB >> 8867084

Intracerebroventricular injection of methylatropine suppresses insulin response to oral glucose load in rats.

H Ohnuma1, K Yamatani, M Igarashi, K Sugiyama, H Manaka, M Tominaga, H Sasaki.   

Abstract

Hepatic glucoreceptor-vagal afferent inputs to the central nervous system and pancreatic vagal efferent stimuli are important for insulin secretion. In the present study, we examined the effect of intracerebroventricular (i.c.v.) injection of atropine methyl bromide (methylatropine) on the insulin response following glucose ingestion in rats. When rats were injected with methylatropine i.c.v., the plasma glucose concentration increased, the insulin response reduced, and glucagon-like peptide-1 (7-36) amide (tGLP-1) was unchanged following an oral glucose load, compared with the controls. The plasma insulin response following an intravenous glucose load was not affected by i.c.v. or intraperitoneal injection of methylatropine. A transient increase in plasma insulin after selective hepatic vagotomy was inhibited by i.c.v. injection of methylatropine. Arterial blood pressure or pulse rate was not changed by i.c.v. injection of methylatropine. These results show that the central nervous system plays an important role in the vagal control of the insulin response to glucose ingestion. In rats, for the insulin response soon after glucose ingestion (early phase insulin response), direct neural control (hepatic vagal afferent-central nervous system-pancreatic vagal efferent) of the islet B cells seems more important than the intestinal insulinotropic hormone, tGLP-1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8867084     DOI: 10.1016/0165-1838(95)00101-8

Source DB:  PubMed          Journal:  J Auton Nerv Syst        ISSN: 0165-1838


  2 in total

Review 1.  Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor.

Authors:  Katrina Weston-Green; Xu-Feng Huang; Chao Deng
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

2.  Repaglinide, but not nateglinide administered supraspinally and spinally exerts an anti-diabetic action in d-glucose fed and streptozotocin-treated mouse models.

Authors:  Yun-Beom Sim; Soo-Hyun Park; Yu-Jung Kang; Sung-Su Kim; Chea-Ha Kim; Su-Jin Kim; Su-Min Lim; Jun-Sub Jung; Ohk-Hyun Ryu; Moon-Gi Choi; Hong-Won Suh
Journal:  Korean J Physiol Pharmacol       Date:  2013-12-16       Impact factor: 2.016

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.